Aerovate Therapeutics Inc... (AVTE)
NASDAQ: AVTE
· Real-Time Price · USD
2.68
0.00 (0.00%)
At close: Apr 28, 2025, 3:59 PM
2.68
0.00%
After-hours: Apr 28, 2025, 04:00 PM EDT
0.00% (1D)
| Bid | 2.66 |
| Market Cap | 77.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -48.96M |
| EPS (ttm) | -59.5 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | -3.39 |
| Analyst | Hold |
| Ask | 2.74 |
| Volume | 981,795 |
| Avg. Volume (20D) | 7,697 |
| Open | 2.66 |
| Previous Close | 2.68 |
| Day's Range | 2.63 - 2.77 |
| 52-Week Range | 2.63 - 884.98 |
| Beta | 0.95 |
About AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2021
Employees 4
Stock Exchange NASDAQ
Ticker Symbol AVTE
Website https://aerovatetx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for AVTE stock is "Hold." The 12-month stock price forecast is $70, which is an increase of 2511.94% from the latest price.
Stock Forecasts6 months ago
+11.87%
Aerovate Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
9 months ago
+8.07%
Aerovate Therapeutics shares are trading higher after the company announced it is exploring strategic alternatives.
